Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) gapped down before the market opened on Friday . The stock had previously closed at $45.16, but opened at $42.70. Greenwich LifeSciences shares last traded at $42.58, with a volume of 1,118 shares.
Separately, HC Wainwright initiated coverage on Greenwich LifeSciences in a research report on Wednesday, September 1st. They issued a “buy” rating and a $78.00 target price on the stock.
The stock’s 50 day moving average is $41.77 and its two-hundred day moving average is $38.77.
Greenwich LifeSciences Company Profile (NASDAQ:GLSI)
Greenwich LifeSciences, Inc, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery.
See Also: Why are percentage gainers important?
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.